Professor Karim Fizazi Archives - Research to Practice

A CME Symposium Held Adjunct with the 2026 ASCO^® Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Continental Room B (Lobby Level)

No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Faculty

Wassim Abida

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Director of Translational Research in Prostate Cancer, Associate Member, Genitourinary Oncology Service

Weill Cornell Medical College, New York, New York

Associate Professor of Medicine

Faculty

Rahul Aggarwal

MD

Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research, Director, Genitourinary Medical Oncology

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Associate Director for Clinical Research

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota, Minneapolis, Minnesota

Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation

Moderator

Rana R McKay

MD

Moores Cancer Center, University of California San Diego, San Diego, California

Professor of Medicine and Urology, Associate Director, Clinical Research, Co-Lead, Genitourinary Program

Faculty

Professor Karim Fizazi

MD, PhD

University of Paris Saclay Centre Oscar Lambret Lille, France

GETUG President

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Not an official event of the 2026 ASCO^® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO^®, Association for Clinical Oncology, or Conquer Cancer^®, the ASCO Foundation.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
Major efficacy and safety data, including overall survival outcomes, from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy
FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) in clinical practice
Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC

MODULE 2: Current Hormonal Treatment for Metastatic HSPC (mHSPC)

Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC
Published data from the Phase III ARANOTE study supporting the recent FDA approval of darolutamide/ADT for mHSPC
Clinical factors guiding the selection of a specific AR pathway inhibitor for patients with mHSPC; available datasets exploring the relative benefits of various approved agents
Published efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
Optimal selection of candidates with mHSPC for triplet therapy with darolutamide/docetaxel/ADT

MODULE 3: Current and Future Role of Regimens Combining PARP Inhibitors and AR Pathway Inhibitors in Treatment for Metastatic Prostate Cancer

Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in patients with metastatic prostate cancer; recommended timing and optimal method for genetic testing
Biological rationale for combining PARP inhibitors with secondary hormonal agents in the treatment of metastatic prostate cancer
Long-term efficacy and safety findings from the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib and abiraterone, niraparib and abiraterone and talazoparib and enzalutamide, respectively, in the first-line setting for patients with metastatic castration-resistant prostate cancer (mCRPC)
FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for mCRPC; appropriate selection of a PARP inhibitor/secondary hormonal therapy combination for individual patients
Presented data from the Phase III AMPLITUDE trial evaluating the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; clinical implications
Ongoing Phase III TALAPRO-3 and EvoPAR-Prostate01 trials evaluating talazoparib and saruparib, respectively, in combination with secondary hormonal therapy for patients with mHSPC; anticipated completion dates

MODULE 4: Emerging Role of AKT Inhibition in Therapy for Patients with mHSPC

Biological justification for targeting the PI3K/AKT/mTOR pathway with capivasertib in prostate cancer; rationale for benefit for patients with PTEN-deficient disease
Frequency of PTEN deficiency in prostate cancer; indications for and optimal timing of and approach to PTEN assessment
Design, eligibility criteria and primary and secondary endpoints of the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
Recently presented positive results from the CAPItello-281 trial with the addition of capivasertib to abiraterone/ADT for PTEN-deficient mHSPC
Spectrum of toxicities associated with capivasertib; recommended monitoring and management strategies
Potential integration of capivasertib/abiraterone/ADT into mHSPC treatment algorithms; optimal use with regard to other currently available regimens

MODULE 5: Current and Future Use of Radiopharmaceuticals for Metastatic Prostate Cancer

Long-term data with and current role of radium-223 monotherapy in mCRPC treatment algorithms
Key efficacy and safety findings from the Phase III PEACE III trial of radium-223 and enzalutamide versus enzalutamide alone as first-line therapy for mCRPC with bone metastases; implications for clinical management
Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated, PSMA-positive mCRPC; appropriate sequencing with regard to other available therapies
Recently presented results from the Phase III PSMAddition study evaluating the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice
Early findings with and ongoing evaluation of other PSMA-targeted radiopharmaceuticals for metastatic prostate cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for patients with consideration of the risks and potential benefits of new and established forms of hormonal therapy.
Appraise published research findings on optimal therapeutic approaches for patients with biochemical recurrence after local therapy for prostate cancer, and counsel appropriate candidates regarding the potential benefits of FDA-approved systemic treatment options.
Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options for patients.
Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into clinical management algorithms.
Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
Review available Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and future clinical role of these strategies.
Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Abida — Advisory Committees: AstraZeneca Pharmaceuticals LP, K36 Therapeutics, Nuvation Bio Inc, ORIC Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boundless Bio, Duality Biologics, Endeavor BioMedicines, Tolmar; Contracted Research: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, K36 Therapeutics, Merus, MOMA Therapeutics, Nuvation Bio Inc, ORIC Pharmaceuticals, TransThera. Dr Aggarwal — Advisory Committees: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Merck, Pfizer Inc; Consulting Agreements: Boxer Capital Management, EcoR1 Capital, Genentech, a member of the Roche Group; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Johnson & Johnson, Merck, Novartis, Zenith Epigenetics; Nonrelevant Financial Relationships: Prostate Cancer Clinical Trials Consortium. Dr Antonarakis — Advisory Committees: Abeona Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus, Vir Biotechnology Inc; Consulting Agreements: Acerand Therapeutics, Blue Earth Diagnostics, Boundless Bio, Clarivate, Clearview Healthcare Partners, Curium, DAVA Oncology, EcoR1 Capital LLC, Global Life Sciences Alliance, Health Monitor Network, Johnson & Johnson, Lilly, Lumanity, Propella Therapeutics Inc, Slingshot Insights, Third Bridge, Z-Alpha; Contracted Research: Actinium Pharmaceuticals Inc, MacroGenics Inc, Merck, MorphoSys, Novartis, Orion Corporation, pharmaand GmbH, Seagen; Patents: Qiagen; Nonrelevant Financial Relationships:Binaytara Foundation, Conexiant, eCancer, Fred Hutch Cancer Center, MJH Life Sciences, Targeted Oncology, The Medical Educator Consortium. Prof Fizazi — Honoraria, Former Institution: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc. Additional faculty to be announced.

MODERATOR
Dr McKay — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

You have successfully registered

See you on Saturday, May 30

Format:

Chicago, IL

Date & Time:

Saturday, May 30 7:00 PM — 9:00 PM CT

This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel*, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.

No fee is charged to attend the session virtually.

NOTICE:
Registration for this event is independent of registration for the 2026 ASCO Annual Meeting.

Register For(Required)

Webinar

In-Person

I am a:(Required)

Clinician / healthcare professional

Other / industry professional

Registration

Name(Required)

First Last

Email(Required)

Address(Required)

City State / Province / Region Country

Clinical background:

Degree(Required)

Specialty(Required)

If you are a clinician, which of the following best describes your practice setting?(Required)

National Provider Identifier (NPI) Number

How did you learn about this symposium:(Required)

Industry registration:

Professional designation(Required)

Institution/Organization

To register for this event, please log in.

Don’t have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Or

Accreditation types: 1.75 ABIM MOC, ABS MOC, CME

Expires: March 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Symposium Video Proceedings

1h 29min

Faculty

Professor Karim Fizazi

MD, PhD

University of Paris Saclay, Centre Oscar Lambret, Lille, France

GETUG President

Faculty

Daniel George

MD

Duke University School of Medicine, Durham, North Carolina

Eleanor Easley Distinguished Chair, Professor of Medicine, Surgery and Urology

Duke Cancer Institute, Durham, North Carolina

ACS Research Professor, Co-Lead, DCI Center for Prostate and Urologic Cancers

Moderator

Elisabeth I Heath

MD

Mayo Clinic, Rochester, Minnesota

Chair, Department of Oncology

TARGET AUDIENCE
This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

Appreciate the incidence and clinical relevance of PTEN deficiency in prostate cancer, and develop an understanding of the optimal method to assess PTEN status in patients.
Assess the clinical and biological factors in the selection of therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in order to optimally personalize treatment recommendations.
Evaluate available Phase III data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency, and consider the potential role of this form of treatment.
Implement a plan of care to recognize and manage side effects and toxicities associated with AKT inhibitors in preparation for their potential availability for patients with prostate cancer.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Proceedings: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCOGU2026/AKTiProstate/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Karim Fizazi, MD, PhD
GETUG President
University of Paris Saclay
Centre Oscar Lambret
Lille, France

Honoraria, Former Institution: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc.

Daniel George, MD
Eleanor Easley Distinguished Chair
Professor of Medicine, Surgery and Urology
Duke University School of Medicine
ACS Research Professor
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina

Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Candel Therapeutics, Convergent Therapeutics Inc, Dendreon Pharmaceuticals LLC, Johnson & Johnson, Merck, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Johnson & Johnson, Novartis, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc, pharmaand GmbH; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Stock Options/Stock — Public Companies: Bristol Myers Squibb, Pfizer Inc; Nonrelevant Financial Relationships: IDEOlogy Health, MJH Life Sciences, Onclive, Targeted Oncology.

CONSULTING CLINICAL INVESTIGATORS — Neeraj Agarwal, MD, FASCO
has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Rana R McKay, MD, FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.

MODERATOR
Elisabeth I Heath, MD
Chair, Department of Oncology
Mayo Clinic
Rochester, Minnesota

Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Gilead Sciences Inc, Novartis, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (to Institution): Novartis; Contracted Research (Research Support to Institution): Altor Bioscience Corporation, Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Clarity Pharmaceuticals, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Janux Therapeutics, Johnson & Johnson, MacroGenics Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Regeneron Pharmaceuticals Inc, Seagen Inc, Xencor; Nonrelevant Financial Relationships (to Institution): Calibr-Skaggs Institute for Innovative Medicines.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Release date: March 2026
Expiration date: March 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr George

Kisiel F et al. Prognostic significance of PTEN loss in prostate cancer: A meta-analysis of Gleason grade and clinical outcomes. Cancers (Basel) 2025;17(17):2862. Abstract

Lotan TL et al. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol 2016;29(8):904-14. Abstract

Maylin ZR et al. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells 2024;13(23):1999. Abstract

Tortorella E et al. AR and PI3K/AKT in prostate cancer: A tale of two interconnected pathways. Int J Mol Sci 2023;24(3):2046. Abstract

Prof Fizazi

de Bono JS et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur Urol 2025;87(6):672-82. Abstract

Fizazi K et al. A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. ESMO 2025;Abstract 2383O.

Sweeney C et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2021;398(10295):131-42. Abstract

Dr Heath

George DJ et al. Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Genitourinary Cancers Symposium 2026;Abstract 14.

Iyengar NM et al. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: Expert opinion. NPJ Breast Cancer 2025;12(1):16. Abstract

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Webinar Video Proceedings

59min
Faculty Presentation: Professor Karim Fizazi, MD, PhD

32min
Faculty Presentation: Emmanuel S Antonarakis, MD

51min

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota, Minneapolis, Minnesota

Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation

Faculty

Professor Karim Fizazi

MD, PhD

University of Paris Saclay, Centre Oscar Lambret, Lille, France

GETUG President

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate individual treatment plans for patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and offer appropriate counseling about the potential benefits of FDA-approved systemic treatment options.
Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options with patients.
Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into clinical management algorithms.
Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate emerging data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and a PTEN deficiency.
Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biological factors.
Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
Review available Phase III data documenting the efficacy of various forms of radioligand therapy for patients with mCRPC, and consider the current and potential clinical role of these strategies.
Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/Prostate/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Emmanuel S Antonarakis, MD
Clark Endowed Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisory Committees: Abeona Therapeutics Inc, AstraZeneca Pharmaceuticals LP, Blue Earth Diagnostics, Boundless Bio, Curium, Forbion, Sanofi, Tango Therapeutics; Consulting Agreements: Acerand Therapeutics, Clarity Pharmaceuticals, Curium, EcoR1 Capital LLC, Health Monitor, Lilly, LinKinVax, Vir Biotechnology Inc, Z-Alpha; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, MacroGenics Inc, Novartis, Orion Corporation, pharmaand GmbH, Seagen Inc.

Professor Karim Fizazi, MD, PhD
Head of Service and Full Professor
Institut Gustave Roussy
University of Paris Saclay
Villejuif, France

Institutional Honoraria: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Release date: May 2025
Expiration date: May 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Agarwal N et al. Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. Genitourinary Cancers Symposium 2025;Abstract LBA18.

Agarwal N et al. Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study. ESMO 2024;Abstract LBA67.

Aggarwal R et al. PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol 2024;42(10):1114-23. Abstract

André F et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380(20):1929-40. Abstract

Azad A et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). Genitourinary Cancers Symposium 2025;Abstract TPS279.

Azad A et al. Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design. Genitourinary Cancers Symposium 2024;Abstract TPS236.

Emmett L et al. Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): Secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2025;26(3):291-9. Abstract

Fizazi K et al. MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results. Genitourinary Cancers Symposium 2024;Abstract 159.

Fizazi K et al. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid 2024;3(1). Abstract

Freedland SJ et al. Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: A post hoc analysis of patient-reported outcomes in the EMBARK study. Eur Urol 2025;87(5):507-11. Abstract

Gillessen S et al. A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. ESMO 2024;Abstract LBA1.

Gomez-Veiga F et al. Clinical outcomes of enzalutamide in metastatic hormone-sensitive prostate cancer in patients aged <75 and 75 years: ARCHES post hoc analysis. Eur Urol Oncol 2024;7(4):860-9. Abstract

Gratzke CJ et al. Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA. Genitourinary Cancers Symposium 2025;Abstract TPS301.

Hadaschik BA et al. PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer. ESMO 2021;Abstract 649TiP.

Hussain MH et al. Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway). Clin Cancer Res 2024;30(19):4318-28. Abstract

Morgans AK et al. Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP). Genitourinary Cancers Symposium 2025;Abstract TPS432.

Morris MJ et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. Lancet 2024;404(10459):1227-39. Abstract

Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract

Parker CC et al. Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: Results from the three-way comparison of RADICALS-HD (NCT00541047). Eur Urol 2024;86(5):422-30. Abstract

Rathkopf DE et al. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). Genitourinary Cancers Symposium 2021;Abstract TPS176.

Roubaud G et al. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. Eur J Cancer 2024;209:114183. Abstract

Roy S et al. Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: An exploratory analysis of the TITAN trial. J Urol 2024;212(5):672-81. Abstract

Saad F et al. Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial. Genitourinary Cancers Symposium 2025;Abstract 219.

Saad F et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 2024;42(36):4271-81. Abstract

Saad F et al. Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: Analyses of the randomized phase 3 ARASENS study. Eur Urol 2024;86(4):329-39. Abstract

Sartor O et al. Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). ESMO 2024;Abstract LBA65.

Schweizer MT et al. Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. Genitourinary Cancers Symposium 2025;Abstract LBA138.

Shore N et al. Apalutamide for high-risk localized prostate cancer following radical prostatectomy (Apa-RP). J Urol 2024;212(5):682-91. Abstract

Shore ND et al. Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age. ESMO 2024;Abstract 1638P.

Turner NC et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med 2024;391(17):1584-96. Abstract

Tutrone R et al. Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study. Eur Urol Oncol 2024;7(4):906-13. Abstract

Yu EY et al. OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy. Genitourinary Cancers Symposium 2025;Abstract TPS286.

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Webinar Video Proceedings

59min
Faculty Presentation: Professor Karim Fizazi, MD, PhD

32min
Faculty Presentation: Emmanuel S Antonarakis, MD

51min

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota, Minneapolis, Minnesota

Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation

Faculty

Professor Karim Fizazi

MD, PhD

University of Paris Saclay, Centre Oscar Lambret, Lille, France

GETUG President

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate individual treatment plans for patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and offer appropriate counseling about the potential benefits of FDA-approved systemic treatment options.
Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options with patients.
Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into clinical management algorithms.
Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate emerging data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and a PTEN deficiency.
Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biological factors.
Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
Review available Phase III data documenting the efficacy of various forms of radioligand therapy for patients with mCRPC, and consider the current and potential clinical role of these strategies.
Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/Prostate/Presentations/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Emmanuel S Antonarakis, MD
Clark Endowed Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisory Committees: Abeona Therapeutics Inc, AstraZeneca Pharmaceuticals LP, Blue Earth Diagnostics, Boundless Bio, Curium, Forbion, Sanofi, Tango Therapeutics; Consulting Agreements: Acerand Therapeutics, Clarity Pharmaceuticals, Curium, EcoR1 Capital LLC, Health Monitor, Lilly, LinKinVax, Vir Biotechnology Inc, Z-Alpha; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, MacroGenics Inc, Novartis, Orion Corporation, pharmaand GmbH, Seagen Inc.

Professor Karim Fizazi, MD, PhD
Head of Service and Full Professor
Institut Gustave Roussy
University of Paris Saclay
Villejuif, France

Institutional Honoraria: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Release date: May 2025
Expiration date: May 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.